Methods for managing cell-derived assets, and cell-derived asset management systems.

Abstract

At the very least, define the culture supernatant as an asset and enable the return of profits to the provider. [Solution] A method for managing cell-derived assets, comprising the steps of: obtaining cell-derived asset identification information relating to cell-derived assets, including at least the culture supernatant, obtained by a cell culture process of iPS cells derived from a first individual who is a cell provider; generating brand information representing brand assets relating to the cell-derived assets using information of the first individual, the cell-derived asset identification information, and business use information of the cell-derived assets; and generating certification information relating to the brand information.

Description

Technical Field

[0001] The present disclosure relates to a system, a method, and a program for managing cell-derived materials as assets and formulating, supplying, dealing with rights, and distributing profits of such assets.

Background Art

[0002] Conventionally, in order to obtain medical or cosmetic effects by using the culture supernatant of iPS cells, pharmaceutical compositions and cosmetics containing the iPS cell culture supernatant obtained by culturing iPS cells are known (Patent Document 1 below).

[0003] However, conventional iPS cell-related services remain at the level of cell banking (storage), and many of them are mainly aimed at future medicine and drug discovery. Therefore, the operation of the asset value during the storage period and the utilization in non-medical fields (such as improving quality of life, beauty, etc.) have not been considered.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] The present disclosure provides a management and operation system, method, and program that define at least the culture supernatant as an asset and enable profit reduction to the provider.

Means for Solving the Problems

[0006] The method for managing cell-derived assets of the present disclosure is as follows: obtaining cell-derived asset identification information regarding a cell-derived asset containing at least a culture supernatant obtained by a culturing process of iPS cells derived from a first individual who is a provider of the cells; A step of generating brand information representing brand assets relating to the cell-derived assets using the first personal information, the cell-derived asset identification information, and the business use information of the cell-derived assets; The process includes the step of generating certification information relating to the aforementioned brand information.

[0007] Furthermore, the cell-derived asset management system for managing the cell-derived assets described herein is: An asset database that registers information of a first individual who is a provider of cells related to the cell-derived assets, cell-derived asset identification information relating to cell-derived assets including at least the culture supernatant obtained by the culture process of iPS cells derived from the first individual, and business use information of the cell-derived assets. A rights management unit manages the aforementioned personal information, the aforementioned business use information, and the allocation conditions in association with each other. The system includes an allocation calculation unit that performs calculations to allocate the sales revenue based on the business use of the cell-derived assets to the first individual using the allocation conditions. [Effects of the Invention]

[0008] According to this disclosure, at least the culture supernatant can be defined as an asset, making it possible to return profits to the provider. [Brief explanation of the drawing]

[0009] [Figure 1] A diagram illustrating the overall business scheme. [Figure 2] Overall diagram of the management and operation system for renewable assets. [Figure 3] A diagram illustrating the hierarchical data structure of renewable assets. [Figure 4] Diagram illustrating the asset acquisition process. [Figure 5] Diagram illustrating the operation and supply flow. [Figure 6] A diagram illustrating the rights processing and distribution calculation flow. [Figure 7] A diagram illustrating the processing flow of NFTs and smart contracts. [Figure 8]An explanatory diagram for assigning and matching identification information in inventory and logistics integration. [Figure 9] Database table relationship diagram (assets, rights holders, transactions, allocation conditions). [Figure 10] A sequence chart of the management and operation methods using this system. [Modes for carrying out the invention]

[0010] The embodiments of this disclosure will be described below with reference to the drawings. In the following description, clinical applications as medical research, clinical trials, and insured medical treatment will be excluded, and the main focus may be on private medical treatment, cosmetic treatment, or related commercial use (regardless of the name, anything provided for consideration is considered commercial use). In particular, the focus may be on cosmetic treatment or related commercial use.

[0011] Figure 1 is a scheme diagram illustrating the business model that this disclosure aims to realize. In this diagram, the iPS provider is the first individual who provides their own cells. The first individual registers with the platform via a terminal and enters provider information (personal information, consent, payment information (wallet address, etc.), contact information, etc.). The cell bank is a facility, company, or system that stores and cultures cell resources (various cells including iPS cells) derived from iPS cell (including cells that become donor-derived material) providers and obtains supernatant through the culture process.

[0012] In this context, assets that can be managed in an iPS cell bank may include not only the iPS cells themselves, but also the donor-derived materials from which they originate, all cell lines and lots derived therefrom, and even reference samples and traceability information managed integrally with them. Specifically, as the "source" of iPS cells, collected specimens such as whole blood, peripheral blood, umbilical cord blood, bone marrow, and skin biopsy samples may be managed along with management information such as donor consent and anonymized IDs. Fractions and recovered fractions obtained from these specimens, such as PBMCs, leukocyte fractions, and CD34-positive cells, as well as associated samples such as plasma and serum in some cases, and reference materials such as genomic DNA, RNA, and cDNA derived from the same donor, and stored samples for infectious disease screening may also be organized as assets. Therefore, cell-derived assets include human-derived iPS cells, iPS cell-derived differentiated cells, or culture supernatants derived from iPS cells or iPS cell-derived differentiated cells, as well as objects created by derivation from iPS cells or iPS cell-derived differentiated cells. Furthermore, the subjects may include those derived from iPS cells or iPS cell-derived differentiated cells, including iPS cells derived from animals other than humans, differentiated cells derived from iPS cells, or culture supernatants derived from iPS cells or differentiated cells derived from iPS cells.

[0013] Furthermore, intermediates before and after reprogramming, such as primary cultured cells including dermal fibroblasts and blood-derived primary cells, immortalized and proliferated cell lines (if applicable), cell populations undergoing reprogramming, early colonies, and candidate clones, may also be subject to management from the perspective of quality, reproducibility, and traceability in subsequent processes. Regarding iPS cells themselves, in addition to single-clonal lines and polyclonal populations, master cell banks (MCBs) and working cell banks (WCBs), distribution vials and backup storage lots, and banks of the same line stored separately according to differences in culture conditions (feeder-dependent, feeder-free, etc.) may each be treated as independent assets.

[0014] Furthermore, as assets derived from iPS cells, various differentiated cell lots such as brown adipocytes, immune system cells (dendritic cells, etc.), fibroblasts, dental pulp cells, hair follicle and pore-related cells, three-dimensional aggregates such as organoids, spheroids, and assembleoids of the brain, intestine, liver, kidney, etc., and lots at the progenitor and precursor cell stages such as neural progenitor cells, cardiomyocyte progenitor cells, and hematopoietic progenitor cells during the differentiation process can also be banked and become targets for asset management from the perspectives of versatility of use and supply.

[0015] In addition, derivative lines subjected to gene modification such as reporter introduction, knockout / knockin, introduction / repair of disease mutations (isogenic pairs), HLA modification, etc., and lines with different clones can be distinguished as separate assets even if the parental strains are the same. Moreover, although not the cells themselves, reference samples (DNA / RNA references derived from the same line, reference samples at the time of freezing, negative / positive control cells, etc.) essential for identity confirmation and quality assurance, as well as certificates of origin, production histories (phylogenetic trees, passages, freezing dates, lot numbers, etc.), test results (identity, purity, microorganisms, karyotype / genome, markers, etc.), agreement documents regarding distribution / transfer (MTA / CTA, etc.), redistribution conditions, records related to import / export, and in some cases operational documents such as standard procedure manuals and culture protocols may also be targets to be managed together with the cells as assets of the cell bank.

[0016] The flow from the cell bank in Figure 1 to the supernatant, preparations for personal use, etc. includes the aspect that the supernatant is used for the provider's own use (self-treatment, aesthetic treatment, etc.). Partner companies (for example, operators of oral preparations, injections, infusions, topical agents, creams, pet products, etc.) illustrate that the supernatant or cell-derived components are not limited to iPS cells but can be obtained from various iPS cell-derived differentiated cells such as brown adipocytes, immune system cells (dendritic cells, etc.), fibroblasts, dental pulp cells, hair follicle and pore-related cells, and can be processed into various dosage forms.

[0017] Figure 1 illustrates a tokenization mechanism in which token identifiers (including NFTs) are assigned and managed for cell resources and supernatants managed by the cell bank. Tokenization here is not necessarily limited to public blockchains, but also includes recording in central registries, permissioned ledgers, verifiable credentials, etc. The token identifier functions as a reference key for subsequent brand asset management, rights referencing, authenticity verification, and revenue tracking. Personal preparations include those prepared using supernatants as raw materials and used by iPS cell providers. This makes it possible to generate brand information representing brand assets related to cell-derived assets using the first individual's information, cell-derived asset identification information, and business use information (for commercial use) of the cell-derived assets. Furthermore, it becomes possible to generate proof information related to this brand information.

[0018] The forms of use for self-administered preparations are diverse, including syringes, intravenous drips, and bottles. Furthermore, information related to specific preparations (preparation conditions, lot information, intended use, etc.) is managed by the platform and linked to information on the supernatant as needed. Self-administered preparations may include, for example, intravenous injection or infusion preparations for treatment at medical institutions such as clinics. These may be used for anti-aging care, circulating components derived from the user's own cells throughout the body. They may also be local injection preparations for targeted treatment of specific areas. These may be used for wrinkle or scalp care. They may also be cosmetics or topical preparations that are easy to incorporate into daily skincare. These may be used in the form of customized beauty creams with ingredients adjusted to the user's skin type and preferences, or bottled beauty serums that maintain freshness. They may also be formulated as supplements, health foods, or oral medications containing supernatant-derived components. Similarly, they may be processed into care preparations for animals other than humans, such as pet dogs, cats, or racehorses.

[0019] The development from supernatant liquid or personal formulations to bespoke cosmetics may involve, for example, a commercial model of providing personalized cosmetics using the supernatant liquid. The form of the formulation may be one of those described in the paragraph above. Bespoke cosmetics are custom products tailored to the individual conditions of the provider (skin type, intended use, acceptable ingredients, formulation range, etc.), and private label (PB) development can be carried out by generalizing such custom products and developing packaging, distribution, and marketing. Private label development is a model of selling products on the market as private brand products originating from the provider.

[0020] For personal formulations and private label products, it is crucial to prove that the product originates from the individual's cell-derived assets. Therefore, it is important to have brand information representing the brand assets related to cell-derived assets, and to prove its authenticity. It is important that the brand information is linked to the individual and the business use. For example, for a private label product derived from iPS cells provided by a professional baseball player to be commercially successful, it could be a recovery body cream or massage gel, or a nutritional supplement for training, based on the concept of reducing muscle fatigue, which is associated with the growth factors contained in the player's cell culture supernatant.

[0021] The center of Figure 1 shows an integrated platform that includes a membership site. This integrated platform may have the following functions: Management of renewable assets (cell-derived assets): Register and manage supernatant fluids, etc., as assets, and integrate cell ID / lot information (cell-derived asset identification information), business use information, provider information, rights information, etc. Membership-based website operation: Providing information touchpoints for providers, fans, and stakeholders through member-only sites and community functions. Private Brand (PB) Asset Sales Site Operation: We sell custom-made cosmetics and PB products through our online shop function. iPS cell donor discovery crowdfunding site operation: Funds are raised from investors and owners and used for initial costs of manufacturing, research, and distribution. These membership-based sites, online shops, and communities demonstrate that the above functions can be integrated on the platform.

[0022] The investing owners include funders such as investors, talent agencies, professional teams / clubs, and entities involved in medical tourism. The arrows from the investing owners to the platform indicate the flow of funds, and the arrows from the platform to the investing owners indicate the distribution of investment profits (returns). This creates a cash flow that covers the costs of manufacturing, processing, and commercializing the supernatant liquid.

[0023] In Figure 1, when a fan uses the service, the platform can award referral fees to iPS providers through membership sites, etc., based on their usage. Referral fees are calculated according to sales and contract type and can be managed as a distribution target. Consumers are the entities that purchase custom-made cosmetics, private label cosmetics, etc., and the display of custom-made private label cosmetics, etc. in the figure exemplifies that they are offered to consumers.

[0024] Clinics, including medical institutions and health checkup facilities, can be providers of preparations derived from supernatant fluid when they are provided in the context of medical treatment or procedures. Clinics can collaborate with the platform and partner companies to provide services under appropriate operational conditions.

[0025] Partner companies include dedicated storage and logistics facilities, research and development facilities in the cosmetics / supplements / health sectors, pharmaceutical research and development facilities, cell culture and processing facilities, testing and analysis institutions, manufacturing plants / raw material and material manufacturers, clinics and health checkup facilities, medical / sports tourism operators and travel agencies, medical malls / tourist hotels, universities and research institutes, etc. These are external functions responsible for the manufacturing, quality evaluation, processing, product development, logistics, sales, medical provision, and related services of the supernatant liquid, and the platform can collaborate with each partner company on data and contractual agreements.

[0026] The system for realizing the scheme based on the above business model will be explained below with the help of diagrams.

[0027] As shown in Figure 2, the renewable asset cell-derived asset management system 1 (hereinafter referred to as "System 1") included in this disclosure may include an asset management server 10, a membership interface 20, a private-label asset sales platform 30, a logistics and storage facility 40, manufacturing equipment 50, and a network N. The membership interface 20 may be accessible using a general-purpose computing device as described later, and provides for identity verification of asset providers, withdrawal requests, agreement to rights and conditions, and reference to transaction history.

[0028] The asset management server 10 may include an asset database 10A, an asset registration unit 10B, a rights management unit 10C, an inventory management unit 10D, and an allocation calculation unit 10E. These may be understood as processing modules that become operational when a processor included in a computing device executes a program stored on a computer-readable medium. The asset database 10A can register assets according to the hierarchical data structure shown in Figure 3. The asset database 10A may be associated with asset ID, origin information, lot number of cell-derived assets (which may be cell-derived asset identification information), quality information, expiration date, storage location, rights holder ID (of a first individual), transaction ID (which may be a transaction ID for commercial use such as business use information), allocation condition ID, etc.

[0029] The asset registration unit 10B may register the date of cell or supernatant collection, differentiation conditions, culture period, culture medium used, processing conditions, test results, and lot status (in production, in stock, shipped, discarded) and manage them together with the asset ID. The rights management unit 10C manages the results of identity verification of rights holders, rights consent history, consented usage information, validity period of allocation conditions, and rights transfer history. The inventory management unit 10D manages storage location, storage temperature zone, last entry / exit time, and storage expiration date and may be used to determine whether or not to issue the goods. The allocation calculation unit 10E may determine the allocation amount by reflecting the sales confirmation date, whether or not there are returns or cancellations, and whether or not there are fee deductions.

[0030] The hierarchical data structure shown in Figure 3 is a diagram illustrating the hierarchical structure of the managed items, from cells to pharmaceutical products, and may consist of (1) human or animal-derived iPS cells (autologous) as the first layer, (2) iPS-derived differentiated cells as the second layer, (3) culture supernatant as the third layer, and (4) processed and purified preparations as the fourth layer. Examples of differentiated cells in the second layer include dendritic cells, brown adipose cells, dental pulp cells, fibroblasts, and dermal papilla cells. It is also possible to directly prepare the culture supernatant for the third layer from the iPS cells in the first layer.

[0031] In Figure 2 again, the membership interface 20 may have the function of receiving instructions from asset providers (owners) for the issuance of assets for personal use or for commercial use. The private-label asset sales platform 30 has a sales function that enables supply to third parties (beauty clinics, manufacturers, etc.) and the development of private-label products. The issuance instructions include the selection of usage category, quantity, recipient, desired unit price, and rights conditions.

[0032] The membership interface 20 may retrieve candidate lots available for shipment from the inventory management department 10D before shipment, and verify and approve compliance with storage expiration dates, temperature zone conditions, and freeze cycle limits. The membership interface 20 may be provided on typical computing devices such as personal computers, tablets, and smartphones, and may be implemented as a web browser or a dedicated application. The private-label asset sales platform 30 can manage contract terms (usage restrictions, resale rights, royalty rates, and units of supply) for each commercial customer and link sales prices and allocation conditions.

[0033] Figure 4 shows a typical asset creation flow. In Figure 4, the steps may be: cell collection and iPS cell conversion → differentiation induction and culture → supernatant extraction → formulation → asset registration (token issuance if necessary). Manufacturing facility 50 is a facility that performs culture, processing, and purification. Logistics and storage facility 40 is a facility that is responsible for designated storage and retrieval. Hereafter, when these are listed as the main components, it basically means that communication will be made via a network to a computing device such as a server. During asset registration, attribute information such as asset ID, manufacturing lot, conformity determination, storage temperature range, and number of freezes will be recorded. Note that, similarly to the above, the culture supernatant may be prepared directly from iPS cells without going through differentiation induction and culture.

[0034] In the differentiation induction and culture process, the conditions for the culture medium, culture period, culture temperature, and cell density are set, and in the processing and purification process, the conditions for each step—filtration, concentration, and sterilization—are registered. The determination of compliance with specifications includes the results of tests such as concentration, purity, sterility, and endotoxin levels, and lots that do not meet the specifications are classified as discarded or reprocessed.

[0035] In the operation and supply flow shown in Figure 5, the stockpile can be issued for self-use (intravenous drip, local injection, cosmetic use, etc.) as Route A, and for commercial use (raw material supply, product supply, private label product development, etc.) as Route B. In Route A, the date and time of self-use, administration method, and amount used may be recorded after the stockpile is issued and made available for reference as a history for reuse. In Route B, instructions may be given via the private asset sales platform 30 to impose restrictions on the recipient's use at the time of stockpile issuance, and sales confirmation processing may be performed based on sales reports from the recipient.

[0036] In the rights processing and distribution calculation flow shown in Figure 6, the distribution calculation unit 10E may perform the calculation process to distribute the revenue obtained from commercial use to asset providers and investors as operating profits and referral fees. The distribution rate and distribution conditions are registered in advance in the rights management unit 10C, and the distribution conditions include the distribution rate, recipient, fee deduction conditions, payment timing, and upper or lower payment limits.

[0037] The allocation calculation unit 10E calculates the amount to be allocated by subtracting settlement fees, logistics costs, and manufacturing costs from the confirmed sales amount, and automatically distributes it according to the allocation conditions. The allocation conditions are defined as a percentage or fixed amount for each recipient: asset providers, introducers, fund managers, and investors, and an update history is saved when the conditions are updated.

[0038] The tokenization process shown in Figure 7 converts asset rights into NFTs, enabling the transfer and trading of those rights. The blockchain can be public (e.g., PoS), private, or consortium type, including public chains such as Ethereum and permissioned chains such as Hyperledger Fabric. The smart contract contains the token ID, asset ID, rights holder's wallet address, distribution rate, distribution destination, fee deduction conditions, payment timing (at the time of sale confirmation or at a regular closing), expiration conditions, freezing conditions, transfer restriction conditions, and audit log reference.

[0039] Tokenization may be performed at any time, such as when the asset is registered or when commercial use begins. Transfer restrictions may include conditions that allow transfer only to specific authorized addresses, or use restrictions that prohibit diversion to medical use. Freezing conditions may include suspension of transfer in the event of a breach of contract, and suspension of protection in the event of a rights dispute.

[0040] Returning to Figure 2, to summarize the above, the membership interface 20 or asset management server 10 may generate brand information representing the brand assets related to the culture supernatant using the asset provider's information, the culture supernatant lot information, and the usage information. The brand information includes information of a first individual who is both the cell provider and the rights holder, cell-derived asset identification information such as cell ID and cell lot, and business usage information of the cell-derived assets, and can be verified.

[0041] The asset management server 10 may generate certification information relating to the brand information, for example, by converting the brand information into a normalized expression, calculating a hash value for the normalized expression, and generating a certification hash. Furthermore, it may issue a token identifier corresponding to the brand asset, record the token identifier in a central registry, an authorized ledger, or verifiable credentials, and associate the certification hash with the record. The asset management server 10 may attach the token identifier and the certification hash to the brand information and output or store it as brand information with token references.

[0042] The commercial flow is also explained below as an example for reference. In the storage facility 40 and logistics network shown in Figure 8, asset and logistics information are linked using identification information such as barcodes or RFID, and the inventory management department 10D manages incoming and outgoing goods. The identification information includes the asset ID and lot number and is used to determine the storage temperature zone and outgoing restrictions. The logistics and storage facility 40 is divided into zones according to the storage temperature zone, and assets are stored in the zone that matches the storage temperature zone of the asset. When goods are received, the identification information is read and verified, and when goods are outgoing, the destination and purpose are recorded.

[0043] Figure 9 shows an example of a data table stored in the asset database. In terms of major table relationships, the asset table, rights holder table, transaction table, and allocation conditions table may be linked by asset ID or rights holder ID. The transaction table records the sales destination, quantity, unit price, and sales confirmation date, and the allocation calculation unit 10E can calculate the allocation amount by referring to the allocation conditions table. The asset table includes asset ID, hierarchical classification, origin information, lot number, conformity status, storage temperature range, and expiration date. The rights holder table includes rights holder ID, identity verification result, wallet address, and contact information. The allocation conditions table may include allocation condition ID, allocation recipient type, allocation rate or fixed amount, fee deduction conditions, payment timing, and validity period.

[0044] An example of a management and operation method using this system will be explained based on the sequence chart shown in Figure 10. The entities in this figure are the asset provider, the membership interface 20, the asset management server 10, the manufacturing equipment 50, the logistics and storage facilities 40, and the private-label asset sales platform 30.

[0045] The asset provider transmits identity verification information and an asset registration application to the membership interface 20. The membership interface 20 transmits the identity verification information to the asset management server 10, and the rights management unit 10C records the identity verification results and the rights consent history.

[0046] The asset management server 10 sends manufacturing instructions to the manufacturing equipment 50, and the manufacturing equipment 50 sends the results of sampling / iPS cell conversion, differentiation induction / culture, processing / purification, and inspection to the asset management server 10. The asset registration unit 10B registers the manufacturing lot, quality information, and conformity determination to the asset database 10A.

[0047] The logistics and storage facility 40 reads identification information when an asset is received and transmits it to the inventory management department 10D, which then updates the storage location, temperature zone, and expiration date. When an asset provider submits a request for withdrawal, the member-only interface 20 inquires with the inventory management department 10D about the possibility of withdrawal and determines the lot that meets the conditions.

[0048] For commercial use, the PB asset sales platform 30 determines the sales conditions and sends transaction information (customer, quantity, unit price, sales confirmation date) to the asset management server 10. The allocation calculation unit 10E calculates the allocation amount based on the allocation conditions, and the rights management unit 10C records the allocation results and rights transfer history.

[0049] When converting assets into NFTs, the rights management unit 10C sets distribution conditions in a smart contract and issues tokens, and the distribution calculation unit 10E automatically performs the distribution process in response to the completion of a transaction.

[0050] The above is merely one example of the process.

[0051] This embodiment is applicable not only to humans but also to animals such as dogs, cats, and thoroughbreds (racehorses). Examples of product forms include intravenous injection formulations, local injection formulations, formulations for use in beauty devices, cosmetics, quasi-drugs, supplements, and health foods.

[0052] As an example, an asset provider capitalizes cells derived from human-derived iPS cells, such as the culture supernatant of fibroblasts, and registers the asset through a membership interface 20. The asset registration unit 10B registers the manufacturing lot, conformity determination, storage temperature range (freezing), and expiration date in the asset database 10A, while the rights management unit 10C records the results of rights holder identity verification and distribution conditions (distribution rate, fee deduction conditions, payment timing).

[0053] The asset provider chooses commercial use and sets supply conditions (usage restrictions, supply quantity, unit price) to the cosmetics manufacturer on the private-label asset sales platform 30. The logistics and storage facility 40 verifies inventory using identification information and dispatches the goods, and confirms sales based on sales reports from the manufacturer. The allocation calculation unit 10E calculates the amount to be allocated after deducting the amount and automatically distributes it to the rights holder and referrer according to the allocation conditions. If necessary, the asset rights are converted into NFTs and conditions are set in the smart contract that allow them to be transferred only to authorized addresses.

[0054] The possible forms of the matters described in the above embodiments are also noted below. [1] A method for managing cell-derived assets, A step of obtaining cell-derived asset identification information relating to cell-derived assets, including at least the culture supernatant, obtained by the cell culture process of iPS cells derived from a first individual who is a cell donor, A step of generating brand information representing brand assets relating to the cell-derived assets using the first personal information, the cell-derived asset identification information, and the business use information of the cell-derived assets; A step of generating proof information relating to the aforementioned brand information, A method for managing cell-derived assets, including those mentioned above. [2] When generating the aforementioned certification information, A method for managing cell-derived assets as described in [1], comprising converting the brand information into a normalized representation, calculating a hash value for the normalized representation, and generating a proof hash. [3] When generating the aforementioned certification information, The steps include issuing a token identifier corresponding to the brand asset, recording the token identifier in a central registry, permissioned ledger, or verifiable credentials, and associating the proof hash with the record; The steps include: adding the token identifier and the proof hash to the brand information and outputting brand information with a token reference; A method for managing cell-derived assets as described in [2], including the method described in [2]. [4] A cell-derived asset management system for managing cell-derived assets, An asset database that registers information of a first individual who is a provider of cells related to the cell-derived assets, cell-derived asset identification information relating to cell-derived assets including at least the culture supernatant obtained by the culture process of iPS cells derived from the first individual, and business use information of the cell-derived assets. A rights management unit manages the aforementioned personal information, the aforementioned business use information, and the allocation conditions in association with each other. An allocation calculation unit that performs calculations to allocate the sales revenue based on the business use of the cell-derived assets to the first individual using the allocation conditions, A cell-derived asset management system equipped with the following features. [5] The cell-derived asset management system according to [4], wherein the cell-derived assets include human-derived iPS cells, differentiated cells derived from the iPS cells, or culture supernatant derived from the iPS cells or differentiated cells derived from the iPS cells. [6] The cell-derived asset management system according to [4] or [5], wherein the rights management unit has a function to tokenize the rights, transactions, or transfers of rights of the first individual relating to the cell-derived assets.

[0055] This concludes the explanation provided in this disclosure. However, the new technologies described herein can be realized in various other forms, and parts of the content may be omitted, modified, or replaced without departing from the spirit of this disclosure. The embodiments and variations thereof shown in this disclosure are also included in the scope and spirit of this disclosure and shall be treated as equivalent and comparable to the technologies protected under the claims. [Explanation of Symbols]

[0056] 1 System 10. Asset Management Server 10A Asset Database 10B Asset Registration Department 10C Rights Management Department 10D Inventory Management Department 10E Allocation Calculation Unit 20 Membership-based interface 30 Private Bank Asset Sales Platform 40 Logistics and storage facilities 50 Manufacturing equipment N Network

Claims

1. A method for managing cell-derived assets using a cell-derived asset management system, The aforementioned cell-derived asset management system is Asset management server, The system includes an asset database that registers information of a first individual who is a provider of cells related to the cell-derived assets, cell-derived asset identification information relating to cell-derived assets including at least the culture supernatant obtained by the culture process of iPS cells derived from the first individual, and business use information of the cell-derived assets. The aforementioned asset management server The steps include: obtaining cell-derived asset identification information from the asset database; A step of generating brand information that includes the first individual information, the cell-derived asset identification information, and the business use information of the cell-derived asset, and that represents brand assets relating to the cell-derived asset, using at least the first individual information, the cell-derived asset identification information, and the business use information of the cell-derived asset; A step of generating proof information relating to the aforementioned brand information, A method for managing cell-derived assets, including those mentioned above.

2. The step of generating the aforementioned certification information is: The aforementioned asset management server The steps include converting the aforementioned brand information into a normalized representation, The steps include: calculating a hash value for the normalized representation and generating a proof hash; The steps include issuing a token identifier corresponding to the brand asset relating to the cell-derived asset, The steps include recording the aforementioned token identifier in a central registry, an authorization ledger, or verifiable credentials, The steps include associating the proof hash with the record, The steps include: adding the token identifier and the proof hash to the brand information and outputting or storing the brand information with a token reference; A method for managing cell-derived assets according to claim 1, including the method described in claim 1.

3. The cell-derived asset management system is A rights management unit manages the aforementioned personal information, the aforementioned business use information, and the allocation conditions in association with each other. A distribution calculation unit calculates the distribution amount to be distributed to the first individual using the distribution conditions based on the sales of the cell-derived assets based on their business use, Furthermore, The aforementioned asset management server The Rights Management Department performs the steps of associating and managing the first personal information, the business use information, and the allocation conditions, Steps to obtain transaction information related to commercial use, The distribution calculation unit calculates the distribution amount to be distributed to the first individual based on the transaction information and the distribution conditions, A method for managing cell-derived assets according to claim 1, further comprising:

4. The asset database includes an asset ID, a rights holder ID, a transaction ID, and an allocation condition ID, In the aforementioned asset database, referencing the information linked to the asset ID, rights holder ID, transaction ID, and allocation condition ID, A method for managing cell-derived assets according to claim 3, comprising the step of identifying allocation conditions corresponding to transaction information relating to the commercial use of the cell-derived assets.

Images